We are pleased to inform you that the Board of Directors of the Company in their meeting held on Monday, October 13, 2025, at the Registered Office of the Company situated at 3B, Patanwala ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' Board has approved a capacity expansion at its Dehradun plant for ointment manufacturing. The current capacity is 180,000 kgs operating at around 80% utilisation, and the company plans to add 360,000 kgs of new capacity, effectively doubling it. The expansion will be carried out within 6 months at an estimated investment of around ₹30 crores. Funding will come from bank overdraft and internal accruals. The company says the expansion is needed to meet captive demand and support sales growth in domestic and international markets.
This is a growth-oriented capex announcement that signals confidence in rising demand, though the ₹30 crore spend will be funded through debt and internal cash, which may pressure near-term cash flows. For shareholders, the key thing to watch is whether the expanded capacity translates into higher revenues and margins over the next 6–12 months.